78 Results for "

neurological function

" in MedChemExpress (MCE) Product Catalog:
Products (78)

78 Results for "neurological function" in MCE Product Catalog:

Cat. No.: HY-175027
Target:  

RIP kinase Ferroptosis

Research Areas:  

Neurological Disease

RIPK1-IN-33 is a blood-brain barrier-permeable and orally active RIPK1 inhibitor, with an IC50 of 0.115 μM. RIPK1-IN-33 demonstrates remarkable anti-ferroptosis activity, radical scavenging capacity (IC50 = 123.3 μM), and anti-lipid peroxidation effects (IC50 = 9.72 μM). RIPK1-IN-33 markedly reduces cerebral infarction volume and improves neurological function scores in transient middle cerebral artery occlusion (tMCAO) model. RIPK1-IN-33 can be used for the study of ischemic stroke .
loading...
    loading...
Cat. No.: HY-165492
CAS No.: 103233-65-4
OPC-14117 is an orally active superoxide radical scavenger that can cross the blood-brain barrier. OPC-14117 inhibits the oxidative stress cascade reaction, significantly reducing the increase in tissue osmotic pressure and alleviating brain edema in the brain contusion model. OPC-14117 blocks the NF-κB-dependent apoptotic pathway in the striatum neuron apoptosis model induced by Quinolinic acid (HY-100807). OPC-14117 can reduce the necrotic volume, protect hippocampal CA3 neurons and restore cognitive function. OPC-14117 can be used to study secondary brain injury and improve neurological prognosis .
loading...
    loading...
Cat. No.: HY-171472
CAS No.: 171961-95-8
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

A-86929 is a highly potent and selective dopamine D1 receptor agonist with a pKi value of 7.3. In the 6-OHDA (HY-B1081)-induced unilateral nigrostriatal lesion rat model, A-86929 significantly induces rotational behavior. It also improves motor function in the MPTP (HY-15608)-induced Parkinson's disease marmoset model. Additionally, A-86929 demonstrates potential therapeutic value in reducing cocaine-seeking behavior in rats and reversing Haloperidol (HY-14538)-induced cognitive deficits in rhesus monkeys. A-86929 can be used for research in neurological disorders .
loading...
    loading...
Cat. No.: HY-148611
CAS No.: 1135037-53-4
Target:  

iGluR

Research Areas:  

Neurological Disease

NSC339614 potassium is a selective GluN1/GluN2C and GluN1/GluN2D receptor enhancer with the activity of enhancing neuronal responses to specific NMDA receptors. NSC339614 potassium can selectively enhance the signaling of GluN1/GluN2C and GluN1/GluN2D receptors without affecting other NMDA receptors. The mechanism of action of NSC339614 potassium does not compete with agonists of L-glutamate or glycine, nor does it depend on membrane potential. The activity of NSC339614 potassium depends on the specific structure of the agonist ligand binding domain, showing its potential as a novel pharmacological agent for studying the function of NMDA receptor subtypes and providing new lead compounds for a variety of neurological diseases .
loading...
    loading...
Cat. No.: HY-187273S
[U- 15N]-Cys-C is the 15N-labeled Cys-C. Cystatin C (Cys-C) is a highly sensitive biomarker of renal function that is unaffected by factors such as age; it is also associated with the pathological progression of oncological, cardiovascular, and neurological diseases. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
loading...
    loading...
Cat. No.: HY-17417B
CAS No.: 51481-60-8
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Naloxone hydrochloride is an orally active opioid receptor antagonist. Naloxone hydrochloride attenuates spinal cord stimulation‑associated anti‑hyperalgesic effects, antagonizes physiologic effects of endogenous opioid peptides linked to central nervous system injury sequelae, functions as a pressor agent to induce modest elevations in mean arterial blood pressure, exerts neuroprotective effects to improve post‑traumatic neurologic motor function, blocks opioid receptor‑mediated amnesic pathways, enhances memory consolidation, reverses Adrenocorticotropic hormone (ACTH) (HY-106373)‑ and epinephrine‑induced amnesia, and potentiates the memory‑facilitatory effects of ACTH and epinephrine .
loading...
    loading...
Cat. No.: HY-W195933
CAS No.: 53268-33-0
Target:  

Endogenous Metabolite

6-Aminopyridine-3-thioamide is a compound with anti-tumor activity that can inhibit the activity of specific enzymes, thereby affecting cell proliferation and survival. 6-Aminopyridine-3-thioamide has also been studied for the inhibition of neurodegenerative diseases and has shown the potential to improve neurological function. The structural characteristics of 6-Aminopyridine-3-thioamide make it an important bioactive molecule in compound development.
loading...
    loading...
Cat. No.: HY-180828
Target:  

NO Synthase

iNOs-IN-8 (Compound 13h) is an efficient and highly selective inducible nitric oxide synthase (iNOS) inhibitor, with an IC50 of 238 nM. iNOs-IN-8 exhibits significant neuroprotective effects in oxygen-glucose deprivation/reoxygenation (OGD/R) and hydrogen peroxide-induced neuronal and endothelial cell damage. iNOs-IN-8 significantly reduces the volume of cerebral infarction and improves neurological function in rat models. iNOs-IN-8 can be used for the study of ischemic stroke .
loading...
    loading...
Cat. No.: HY-FLB0739A
CAS No.: 33818-15-4
Synonyms: Cytidine diphosphate-choline sodium solution; CDP-Choline sodium solution; Cytidine 5'-diphosphocholine sodium solution
Citicoline solution is mainly composed of Citicoline sodium (HY-B0739A). Citicoline sodium is an endogenous intermediate in the synthesis of phosphatidylcholine which is a component of cell membranes. Citicoline sodium inhibits reactive oxygen species (ROS) and apoptosis. Citicoline sodium helps promote brain metabolism by reducing blood resistance in the brain and increasing blood flow. Citicoline sodium has certain effects in facilitating brain function recovery and promoting awakening, and can be used for neurological disease and hearing loss study .
loading...
    loading...
Cat. No.: HY-183654
Vadadustat prodrug-1 is a near-infrared activated photocaged, blood-brain barrier-permeable neuroprotective prodrug of Vadadustat (HY-101277). Vadadustat prodrug-1 masks the acidic pharmacophore of Vadadustat, and releases active Vadadustat upon irradiation at 650 nm to inhibit PHD2. Vadadustat prodrug-1 reduces cell damage, infarct volume and cerebral edema, and promotes neurological function recovery. Vadadustat prodrug-1 can be used for the research of ischemic stroke .
loading...
    loading...
Cat. No.: HY-186316
CAS No.: 2769053-56-5
KDS12025 is a blood-brain barrier-permeable, orally active H2O2-decomposing peroxidase enhancer. KDS12025 enhances the H2O2-decomposing pseudoperoxidase activity of Hb without altering oxygen transport function, and reduces intracellular H2O2 load. KDS12025 reduces abnormal H2O2 levels and inhibits the production of COL1. KDS12025 restores cerebral blood flow, maintains neuronal excitability, membrane properties, synaptic connections and corticospinal tract fibers, reduces cerebral edema and exerts neuroprotective effects. KDS12025 improves motor function and overall neurological function. KDS12025 can be used in the research of ischemic stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, aging-related neurodegenerative diseases and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-Y0282
CAS No.: 7647-15-6
Synonyms: NSC 77384; Sanibrom 40
Research Areas:  

Neurological Disease

Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .
loading...
    loading...
Cat. No.: HY-L203
351 compounds

Methylation is an epigenetic modification mechanism that involves adding methyl groups to molecules such as DNA and histones, which can alter gene expression without changing the DNA sequence. This process is catalyzed by enzymes such as DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs), and can be reversed by demethylases. The balance of methylation and demethylation is crucial for maintaining cellular function and genomic stability. Abnormal regulation of methylation may lead to a variety of diseases, including cancer, neurological disorders, and developmental abnormalities. A deep understanding of the molecular mechanisms of methylation metabolism is essential for developing therapeutic strategies for diseases associated with methylation dysregulation.

MCE contains 351 compounds targeting methylation/demethylation enzymes, which is of significant value for studying the pathways of methylation metabolism and exploring their mechanisms of action in diseases.

Cat. No.: HY-186073
CAS No.: 300399-36-4
Target:  

HDAC

Research Areas:  

Neurological Disease

HDAC1 activator-1 is a specific HDAC1 activator with orally activity, exerting no significant effects on other HDAC family members. HDAC1 activator-1 exhibits neuroprotective activity, ameliorates cognitive and motor function deficits by reducing neuronal loss and gliosis. HDAC1 activator-1 specifically activates HDAC1 in SH-SY5Y cells and exerts regulatory effects on aberrant cell cycle and DNA damage. HDAC1 activator-1 can be used for the research of TDP-43 proteinopat1-related neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS) and cerebral ischemia-related neurological injury .
loading...
    loading...
Cat. No.: HY-N18667
CAS No.: 84696-21-9
Centella asiatica extract is an orally active herbal extract. Centella asiatica extract scavenges free radicals, increases stratum corneum hydration, improves epidermal barrier function, and reduces skin redness and skin pH. Centella asiatica extract inhibits pro-inflammatory cytokines, suppresses p38 MAPK phosphorylation, reduces mast cell infiltration, and decreases the expression of TNF-α, IL-4, IL-5, IL-6, IL-17, CXCL9, iNOS and COX-2. Centella asiatica extract upregulates the expression of BDNF and downregulates the expression of VGLUT1, and exhibits neuroprotective effects under hypoxic conditions. Centella asiatica extract inhibits pro-inflammatory M1 macrophage polarization and prevents adipose tissue senescence. Centella asiatica extract can be used in studies related to hypoxia-induced neurological dysfunction, atopic dermatitis, and obesity-induced insulin resistance .
loading...
    loading...
Cat. No.: HY-L089
1,182 compounds

Mitochondria plays an important role in many vital processes in cells, including energy production, fatty-acid oxidation and the Tricarboxylic Acid (TCA) cycle, calcium signaling, permeability transition, apoptosis and heat production. At present, it is recognized that many diseases are associated with impaired mitochondrial function, such as increased accumulation of ROS and decreased OXPHOS and ATP production. Mitochondria are recognized as one of the most important targets for new drug design in cancer, cardiovascular, and neurological diseases, etc. Some small molecule drugs or biologics can act on mitochondria through various pathways, including ETC inhibition, OXPHOS uncoupling, mitochondrial Ca2+ modulation, and control of oxidative stress via decrease or increase of mitochondrial ROS accumulation.

MCE supplies a unique collection of 1,182 mitochondria-targeted compound that mainly targeting Mitochondrial Metabolism, ATP Synthase, Mitophagy, Reactive Oxygen Species, etc. MCE Mitochondria-Targeted Compound Library is a useful tool for mitochondria-targeted drug discovery and related research.

Cat. No.: HY-L013
3,961 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 3,961 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Cat. No.: HY-L923
9000 compounds

Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.

MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.